Literature DB >> 17908964

Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

Yinghui Guan1, Wen-Lin Kuo, Jackie L Stilwell, Hirokuni Takano, Anna V Lapuk, Jane Fridlyand, Jian-Hua Mao, Mamie Yu, Melinda A Miller, Jennifer L Santos, Steve E Kalloger, Joseph W Carlson, David G Ginzinger, Susan E Celniker, Gordon B Mills, David G Huntsman, Joe W Gray.   

Abstract

PURPOSE: This study was designed to elucidate the role of amplification at 8q24 in the pathophysiology of ovarian and breast cancer because increased copy number at this locus is one of the most frequent genomic abnormalities in these cancers. EXPERIMENTAL
DESIGN: To accomplish this, we assessed the association of amplification at 8q24 with outcome in ovarian cancers using fluorescence in situ hybridization to tissue microarrays and measured responses of ovarian and breast cancer cell lines to specific small interfering RNAs against the oncogene MYC and a putative noncoding RNA, PVT1, both of which map to 8q24.
RESULTS: Amplification of 8q24 was associated with significantly reduced survival duration. In addition, small interfering RNA-mediated reduction in either PVT1 or MYC expression inhibited proliferation in breast and ovarian cancer cell lines in which they were both amplified and overexpressed but not in lines in which they were not amplified/overexpressed. Inhibition of PVT1 expression also induced a strong apoptotic response in cell lines in which it was overexpressed but not in lines in which it was not amplified/overexpressed. Inhibition of MYC, on the other hand, did not induce an apoptotic response in cell lines in which MYC was amplified and overexpressed.
CONCLUSIONS: These results suggest that MYC and PVT1 contribute independently to ovarian and breast pathogenesis when overexpressed because of genomic abnormalities. They also suggest that PVT1-mediated inhibition of apoptosis may explain why amplification of 8q24 is associated with reduced survival duration in patients treated with agents that act through apoptotic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908964     DOI: 10.1158/1078-0432.CCR-06-2882

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  190 in total

1.  p53-Dependent induction of PVT1 and miR-1204.

Authors:  Anthony M Barsotti; Rachel Beckerman; Oleg Laptenko; Konrad Huppi; Natasha J Caplen; Carol Prives
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

2.  p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Authors:  Tulsiram Prathapam; Alexey Aleshin; Yinghui Guan; Joe W Gray; G Steven Martin
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

3.  Amplification of lncRNA PVT1 promotes ovarian cancer proliferation by binding to miR-140.

Authors:  Yuqin Ding; Qianjin Fang; Yan Li; Yanni Wang
Journal:  Mamm Genome       Date:  2019-06-20       Impact factor: 2.957

4.  LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer.

Authors:  Jing Zhao; Peizhun Du; Peng Cui; Yunyun Qin; Cheng'en Hu; Jing Wu; Zhongwen Zhou; Wenhong Zhang; Lunxiu Qin; Guangjian Huang
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

5.  Cardiac hypertrophy is positively regulated by long non-coding RNA PVT1.

Authors:  Yi-Hui Yu; Zuo-Ying Hu; Ming-Hui Li; Bing Li; Zhi-Mei Wang; Shao-Liang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Xiaoyan Liu; Lei Bi; Qin Wang; Mingxin Wen; Ce Li; Yidan Ren; Qinlian Jiao; Jian-Hua Mao; Chuanxin Wang; Guangwei Wei; Yunshan Wang
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

7.  Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.

Authors:  Di Cui; Cai-Hua Yu; Min Liu; Qing-Qing Xia; Yu-Feng Zhang; Wei-Long Jiang
Journal:  Tumour Biol       Date:  2015-10-21

8.  Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.

Authors:  Manasa Ramakrishna; Louise H Williams; Samantha E Boyle; Jennifer L Bearfoot; Anita Sridhar; Terence P Speed; Kylie L Gorringe; Ian G Campbell
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

9.  Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Authors:  Kylie L Gorringe; Joshy George; Michael S Anglesio; Manasa Ramakrishna; Dariush Etemadmoghadam; Prue Cowin; Anita Sridhar; Louise H Williams; Samantha E Boyle; Nozomu Yanaihara; Aikou Okamoto; Mitsuyoshi Urashima; Gordon K Smyth; Ian G Campbell; David D L Bowtell
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

10.  A small-cell lung cancer genome with complex signatures of tobacco exposure.

Authors:  Erin D Pleasance; Philip J Stephens; Sarah O'Meara; David J McBride; Alison Meynert; David Jones; Meng-Lay Lin; David Beare; King Wai Lau; Chris Greenman; Ignacio Varela; Serena Nik-Zainal; Helen R Davies; Gonzalo R Ordoñez; Laura J Mudie; Calli Latimer; Sarah Edkins; Lucy Stebbings; Lina Chen; Mingming Jia; Catherine Leroy; John Marshall; Andrew Menzies; Adam Butler; Jon W Teague; Jonathon Mangion; Yongming A Sun; Stephen F McLaughlin; Heather E Peckham; Eric F Tsung; Gina L Costa; Clarence C Lee; John D Minna; Adi Gazdar; Ewan Birney; Michael D Rhodes; Kevin J McKernan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.